Our Services
Core Team
Consulting Network
Resources
- Case Studies
- Blog
- News
- Whitepapers
Careers
Contact

Blog

news and resources
Blog

All
Product Development
Business Development
Clinical Development
Strategy & Commercialization
Valuations
Regulatory Affairs
Opportunity Mapping
Research & IP evaluation
Business Strategy
Cell Therapy
Clinical Development Strategy
Due Diligence
Fibrosis
Microbiome
New Product Planning
Oncology
Partnering
Partnering & deal-making
Pharma Licensing
Technology Transfer

NASH Cirrhosis Space Poised to Heat Up

Title: NASH Cirrhosis Space Poised to Heat Up Author: Peter G. Traber, MD NASH cirrhosis is the most advanced classification of fibrosis progression in fatty liver disease. Results of clinical trials...

Madrigal’s and Viking’s NASH Drugs: Who’s best in class?

Title: Madrigal’s and Viking’s NASH Drugs: Who’s best in class? Author: Peter G. Traber, MD Two companies, Madrigal Pharmaceuticals (NASDAQ: MDGL) and Viking Therapeutics (NASDAQ: VKTX), this year...

NASH Bubble?

Title: NASH Bubble? Author: Peter G. Traber, MD Non-alcoholic fatty liver disease (NAFLD) and Non-alcoholic steatohepatitis (NASH) have been the subject of intense interest in the biotech/pharma...

Identifying Best Disease Indications for Anti-Fibrotic Drugs

Identifying Best Disease Indications for Anti-Fibrotic Drugs By Peter G. Traber, MD

mRNA vaccines: ready for prime time?

by Alex Yule, PhD, Associate, Alacrita Consulting

Senolytics- taking aim at ageing cells

by Alex Yule, PhD, Associate, Alacrita Consulting

Drugs and the human gut microbiome – beyond antibiotics

by Saadia Basharat, PhD, Consultant and Ashley Clark, Consultant Intern at Alacrita

How to start a biotech company

How to start a biotech company by Rob Johnson, Managing Partner and Jess Hearn, Consultant, at Alacrita

Why is it so daunting for US biotech and pharma to launch drugs in Europe themselves?

by Anna Casse, Managing Partner and Saadia Basharat, Consultant, at Alacrita

How best to Prioritize the IP Portfolio in Universities, Charities and Research Funding Bodies?

by Saadia Basharat, PhD, Consultant, Alacrita

What’s the difference between biotech and pharma?

What’s the difference between biotech and pharma? How are biotechnology drugs different from traditional pharmaceuticals, and how are biotech companies different to pharma companies?

Brexit: What are the options for UK registered MAHs?

By Saadia Basharat, PhD, Consultant

1 ... 2 3 4 5 6

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

Strategy and Commercialization Learn more
Product Development Learn more
Business Development Learn more

© 2009-24 Alacrita Holdings Limited | Pharma & Biotech Consulting

Privacy Notice

Alacrita Consulting
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608

One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.